Literature DB >> 4024887

Three-year results of combined modality therapy in locally advanced, resectable squamous cell carcinoma of the head and neck.

K Böheim, H Spoendlin.   

Abstract

Results of a combined therapy, consisting of preoperative chemotherapy, radical resection and postoperative irradiation, of 51 locally advanced, previously untreated, resectable squamous cancers of the head and neck are reported. The overall response rate to chemotherapy was 58.5% (with 33% complete remissions) and higher in carcinomas of the oral cavity and hypopharynx than of the supraglottis and oropharynx. Three year survival was 53% for the entire group, 75% for hypopharyngeal, 58% for oral, 50% for supraglottic and 32% for oropharyngeal lesions, in responders to chemotherapy statistically significant higher than in non responders and only 18% in the fifteen patients who developed recurrences.

Entities:  

Mesh:

Year:  1985        PMID: 4024887     DOI: 10.3109/00016488509108598

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  5 in total

1.  Chemotherapy in head and neck cancer with bleomycin, cisplatinum, and methotrexate.

Authors:  T Deitmer; D Urbanitz
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 2.  Chemotherapeutic management of head and neck cancer.

Authors:  M Al-Sarraf
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology.

Authors:  K Böheim; E Bichler
Journal:  Arch Otorhinolaryngol       Date:  1985

4.  Nutritional and immunological investigations in head and neck cancer patients before and after therapy.

Authors:  H Picker; E Bichler
Journal:  Arch Otorhinolaryngol       Date:  1985

5.  The prognostic influence of induction chemotherapy on advanced head and neck carcinoma.

Authors:  H Picker; N Zingerle; K Böheim; A Lochs; H Spoendlin
Journal:  Arch Otorhinolaryngol       Date:  1986
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.